BTG falls despite positive update
Shares in healthcare specialist BTG fell nearly four per cent yesterday despite the FTSE 250 firm reporting trading that was in line with forecasts. The company, which specialises in commercialising products that target critical care, cancer and vascular disease, has reiterated its revenue guidance of between £275m to £285m for the current financial year following two recent acquisitions. Several negative broker notes helped push the shares to a close of 583p.